1174 related articles for article (PubMed ID: 34381216)
1. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.
Kabinger F; Stiller C; Schmitzová J; Dienemann C; Kokic G; Hillen HS; Höbartner C; Cramer P
Nat Struct Mol Biol; 2021 Sep; 28(9):740-746. PubMed ID: 34381216
[TBL] [Abstract][Full Text] [Related]
2. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
Gordon CJ; Tchesnokov EP; Schinazi RF; Götte M
J Biol Chem; 2021 Jul; 297(1):100770. PubMed ID: 33989635
[TBL] [Abstract][Full Text] [Related]
3. Molnupiravir: coding for catastrophe.
Malone B; Campbell EA
Nat Struct Mol Biol; 2021 Sep; 28(9):706-708. PubMed ID: 34518697
[No Abstract] [Full Text] [Related]
4. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
Menéndez-Arias L
J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
[TBL] [Abstract][Full Text] [Related]
5. Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses.
Wang Y; Li P; Solanki K; Li Y; Ma Z; Peppelenbosch MP; Baig MS; Pan Q
Virology; 2021 Dec; 564():33-38. PubMed ID: 34619630
[TBL] [Abstract][Full Text] [Related]
6. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes.
Sanderson T; Hisner R; Donovan-Banfield I; Hartman H; Løchen A; Peacock TP; Ruis C
Nature; 2023 Nov; 623(7987):594-600. PubMed ID: 37748513
[TBL] [Abstract][Full Text] [Related]
7. A computational comparative analysis of the binding mechanism of molnupiravir's active metabolite to RNA-dependent RNA polymerase of wild-type and Delta subvariant AY.4 of SARS-CoV-2.
Celik I; Tallei TE
J Cell Biochem; 2022 Apr; 123(4):807-818. PubMed ID: 35132671
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 RdRp uses NDPs as a substrate and is able to incorporate NHC into RNA from diphosphate form molnupiravir.
Wang M; Wu C; Liu N; Zhang F; Dong H; Wang S; Chen M; Jiang X; Zhang K; Gu L
Int J Biol Macromol; 2023 Jan; 226():946-955. PubMed ID: 36528144
[TBL] [Abstract][Full Text] [Related]
9. Lethal mutagenesis as an antiviral strategy.
Swanstrom R; Schinazi RF
Science; 2022 Feb; 375(6580):497-498. PubMed ID: 35113690
[TBL] [Abstract][Full Text] [Related]
10. RdRp inhibitors and COVID-19: Is molnupiravir a good option?
Hashemian SMR; Pourhanifeh MH; Hamblin MR; Shahrzad MK; Mirzaei H
Biomed Pharmacother; 2022 Feb; 146():112517. PubMed ID: 34902743
[TBL] [Abstract][Full Text] [Related]
11. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.
Zhou S; Hill CS; Sarkar S; Tse LV; Woodburn BMD; Schinazi RF; Sheahan TP; Baric RS; Heise MT; Swanstrom R
J Infect Dis; 2021 Aug; 224(3):415-419. PubMed ID: 33961695
[TBL] [Abstract][Full Text] [Related]
12. Small-Molecule Antiviral β-d-
Agostini ML; Pruijssers AJ; Chappell JD; Gribble J; Lu X; Andres EL; Bluemling GR; Lockwood MA; Sheahan TP; Sims AC; Natchus MG; Saindane M; Kolykhalov AA; Painter GR; Baric RS; Denison MR
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578288
[TBL] [Abstract][Full Text] [Related]
13. Computational Analysis of Molnupiravir.
Sharov AV; Burkhanova TM; Taskın Tok T; Babashkina MG; Safin DA
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163429
[TBL] [Abstract][Full Text] [Related]
14. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Sheahan TP; Sims AC; Zhou S; Graham RL; Pruijssers AJ; Agostini ML; Leist SR; Schäfer A; Dinnon KH; Stevens LJ; Chappell JD; Lu X; Hughes TM; George AS; Hill CS; Montgomery SA; Brown AJ; Bluemling GR; Natchus MG; Saindane M; Kolykhalov AA; Painter G; Harcourt J; Tamin A; Thornburg NJ; Swanstrom R; Denison MR; Baric RS
Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32253226
[TBL] [Abstract][Full Text] [Related]
15. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
Yip AJW; Low ZY; Chow VTK; Lal SK
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815
[TBL] [Abstract][Full Text] [Related]
16. Molnupiravir; molecular and functional descriptors of mitochondrial safety.
Wallace KB; Bjork JA
Toxicol Appl Pharmacol; 2022 May; 442():116003. PubMed ID: 35358570
[TBL] [Abstract][Full Text] [Related]
17. Molnupiravir: Mechanism of action, clinical, and translational science.
Maas BM; Strizki J; Miller RR; Kumar S; Brown M; Johnson MG; Cheng M; De Anda C; Rizk ML; Stone JA
Clin Transl Sci; 2024 Feb; 17(2):e13732. PubMed ID: 38593352
[TBL] [Abstract][Full Text] [Related]
18. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H
J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098
[TBL] [Abstract][Full Text] [Related]
19. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
Shannon A; Le NT; Selisko B; Eydoux C; Alvarez K; Guillemot JC; Decroly E; Peersen O; Ferron F; Canard B
Antiviral Res; 2020 Jun; 178():104793. PubMed ID: 32283108
[TBL] [Abstract][Full Text] [Related]
20. Molnupiravir for the treatment of COVID-19.
Santani BG; LeBlanc BW; Thakare RP
Drugs Today (Barc); 2022 Jul; 58(7):335-350. PubMed ID: 35851869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
